0001104659-22-110797.txt : 20221024 0001104659-22-110797.hdr.sgml : 20221024 20221024091444 ACCESSION NUMBER: 0001104659-22-110797 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221020 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221024 DATE AS OF CHANGE: 20221024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AZIYO BIOLOGICS, INC. CENTRAL INDEX KEY: 0001708527 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474790334 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39577 FILM NUMBER: 221324934 BUSINESS ADDRESS: STREET 1: 12510 PROSPERITY DRIVE STREET 2: SUITE 370 CITY: SILVER SPRING STATE: MD ZIP: 20904 BUSINESS PHONE: 240-247-1143 MAIL ADDRESS: STREET 1: 12510 PROSPERITY DRIVE STREET 2: SUITE 370 CITY: SILVER SPRING STATE: MD ZIP: 20904 8-K 1 tm2228791d1_8k.htm FORM 8-K
0001708527 false 0001708527 2022-10-20 2022-10-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 20, 2022

 

 

 

AZIYO BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39577   47-4790334

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

12510 Prosperity Drive, Suite 370
Silver Spring, MD 20904 

(Address of principal executive offices) (Zip Code)

 

(240) 247-1170 

(Registrant’s telephone number, include area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbols		   Name of each exchange on which
registered
Class A Common Stock, $0.001 par value per share   AZYO   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On October 20, 2022, the Board of Directors (the “Board”) of Aziyo Biologics, Inc. (the “Company”) increased the size of the Board from a total of five to six directors and appointed David Colpman to the Board, effective immediately. Mr. Colpman will serve as a Class III director for a term expiring at the Company’s annual meeting of stockholders to be held in 2023 and until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Colpman was also appointed to the audit committee of the Board, effective immediately.

 

Mr. Colpman was the managing partner of Colpman Consulting Ltd., a business development consultancy, from July 2014 to March 2020. Prior to this, Mr. Colpman was a senior vice president at Shire Plc from 1999 to 2014. Prior to Shire Plc, Mr. Colpman had senior roles in business development at Novo Nordisk A/S, Glaxo Wellcome Plc and Boots Pharmaceuticals Ltd. Mr. Colpman currently serves on the board of OakHill Bio, a private clinical-stage neonatology and rare disease therapeutics company. In addition, he is currently an advisor to HighCape Capital, an affiliate of HighCape Partners, which is an investment fund and a controlling stockholder of the Company. Mr. Colpman received a B.Sc. from Portsmouth University in the field of pharmacy.

 

The Board has determined that Mr. Colpman qualifies as independent under the rules and regulations of the Nasdaq Stock Market LLC (“Nasdaq”) and the Securities and Exchange Commission rules regarding audit committee membership.

 

As previously disclosed, in connection with C. Randal Mills, Ph.D.’s appointment as Interim President and Chief Executive Officer, Dr. Mills ceased serving as a member of the Company’s Audit Committee and, on June 21, 2022, the Company notified Nasdaq regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2) (“Rule 5605(c)(2)”), which requires, among other things, that the audit committee be comprised of a minimum of three directors who meet the applicable independence requirements under the Nasdaq rules. Effective as of Mr. Colpman’s appointment to the Audit Committee, the Company has regained compliance with Rule 5605(c)(2).

 

In connection with his service as a non-employee director, Mr. Colpman is eligible to participate in the Company’s Non-Employee Director Compensation Policy and will receive compensation as described in such policy, which is filed as Exhibit 10.3 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

 

Mr. Colpman is expected to enter into the Company’s standard indemnification agreement for directors and officers.

 

Item 7.01.Regulation FD Disclosure.

 

The Company issued a press release to announce the appointment of Mr. Colpman. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.

 

The information in this Item 7.01 (including Exhibit 99.1) of this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.Description

 

99.1Press Release of Aziyo Biologics, Inc., dated October 24, 2022

 

104Cover Page Interactive Data File (formatted as Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AZIYO BIOLOGICS, INC.  
     
Date: October 24, 2022 By:   /s/ Matthew Ferguson  
      Matthew Ferguson
      Chief Financial Officer  

 

 

 

 EX-99.1 2 tm2228791d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Aziyo Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of Directors

 

Industry veteran brings more than 25 years of healthcare business development and transaction experience

 

SILVER SPRING, Md., October 24, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced the appointment of David Colpman to its Board of Directors and audit committee, effective October 20, 2022. His appointment brings the company’s Board of Directors to six members.

 

“David’s impressive commercial expertise was vital in guiding some of the world’s largest and most-well respected biopharmaceutical companies in achieving their growth milestones,” said Dr. Randy Mills, Chief Executive Officer of Aziyo Biologics. “We specifically sought a Board member, like David, whose deep industry insights and business development and transaction experience will prove valuable to us as we execute on our near-term priorities. We welcome David’s contributions as we continue to build potential best-in-class products, take advantage of favorable market dynamics and engage in robust commercial discussions regarding strategic partnerships.”

 

Colpman was the managing partner of Colpman Consulting Ltd., a business development consultancy, from July 2014 to March 2020. Prior to this, he was a senior vice president at Shire Plc from 1999 to 2014. Prior to Shire Plc, Colpman had senior roles in business development at Novo Nordisk A/S, Glaxo Wellcome Plc and Boots Pharmaceuticals Ltd. Colpman currently serves on the board of OakHill Bio, a private clinical-stage neonatology and rare disease therapeutics company. In addition, he is currently an advisor to HighCape Capital, an affiliate of HighCape Partners, which is an investment fund and a controlling stockholder of the Company. Colpman received a B.Sc. from Portsmouth University in the field of pharmacy.

 

“I am excited to join Aziyo’s Board of Directors at such a critical time in the Company’s growth,” said Mr. Colpman. “I look forward to leveraging my industry connections to help the Aziyo team realize the value of its pipeline of innovative regenerative therapies and position the business for future commercial success.”

 

About Aziyo Biologics

 

Aziyo Biologics is a regenerative medicine company with a commercial portfolio of differentiated products focused on improving outcomes in patients undergoing a range of surgical procedures, primarily for implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit www.Aziyo.com.

 

 

 

 

Forward-Looking Statements

 

Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited, to statements regarding the Company’s advancement of its strategic and financial objectives, development of its products and its business potential. Forward-looking statements may be identified by words such as “anticipates,” “believe,” “continue,” “expect,” “goal,” “intend,” “may,” “plan to,” “potential,” “projects,” “will,” and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, without limitation, the risks referred to under the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, as such factors may be updated from time to time in the Company’s other filings with the Securities and Exchange Commission (“SEC”), which filings are accessible on the SEC’s website at www.sec.gov and the Investors page of the Company’s website at https://investors.aziyo.com. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company has no obligation to update or revise any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise.

 

Investors:
Matt Ferguson

Aziyo Biologics, Inc.

investors@aziyo.com

 

Media:
Courtney Guyer

Aziyo Biologics, Inc.

PR@aziyo.com

 

 

 

 EX-101.SCH 3 azyo-20221020.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 azyo-20221020_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 azyo-20221020_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Oct. 20, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 20, 2022
Entity File Number 001-39577
Entity Registrant Name AZIYO BIOLOGICS, INC.
Entity Central Index Key 0001708527
Entity Tax Identification Number 47-4790334
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 12510 Prosperity Drive
Entity Address, Address Line Two Suite 370
Entity Address, City or Town Silver Spring
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20904
City Area Code 240
Local Phone Number 247-1170
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.001 par value per share
Trading Symbol AZYO
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 tm2228791d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001708527 2022-10-20 2022-10-20 iso4217:USD shares iso4217:USD shares 0001708527 false 8-K 2022-10-20 AZIYO BIOLOGICS, INC. DE 001-39577 47-4790334 12510 Prosperity Drive Suite 370 Silver Spring MD 20904 240 247-1170 false false false false Class A Common Stock, $0.001 par value per share AZYO NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://aziyo.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2228791d1_8k.htm azyo-20221020.xsd azyo-20221020_lab.xml azyo-20221020_pre.xml tm2228791d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2228791d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2228791d1_8k.htm" ] }, "labelLink": { "local": [ "azyo-20221020_lab.xml" ] }, "presentationLink": { "local": [ "azyo-20221020_pre.xml" ] }, "schema": { "local": [ "azyo-20221020.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "azyo", "nsuri": "http://aziyo.com/20221020", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2228791d1_8k.htm", "contextRef": "From2022-10-20to2022-10-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://aziyo.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2228791d1_8k.htm", "contextRef": "From2022-10-20to2022-10-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://aziyo.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-110797-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-110797-xbrl.zip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end